Pharmaceuticals international, which has been in violation of lender agreements since Wednesday, are beginning to demand new terms that could pile further pressure on the drugmaker's business model, according to three people familiar with the matter. Valeant said on Tuesday that it would not meet a March 15 deadline for filing its annual financial statements with securities regulators, putting it at risk of breaching loan covenants and in danger of defaulting on its US$30bn debt load. It also sharply reduced forecasts for 2016 profits.
展开▼
